Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription

Articles published in Oncogene

Retrieve available abstracts of 144 articles:
HTML format

Single Articles

    July 2022
  1. BELL ES, Shah P, Zuela-Sopilniak N, Kim D, et al
    Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer.
    Oncogene. 2022 Jul 27. pii: 10.1038/s41388-022-02420.
    PubMed     Abstract available

  2. GU Y, Gao H, Zhang H, John A, et al
    TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer.
    Oncogene. 2022 Jul 21. pii: 10.1038/s41388-022-02415.
    PubMed     Abstract available

  3. LIU C, Wang J, Zheng Y, Zhu Y, et al
    Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin alphavbeta3.
    Oncogene. 2022 Jul 19. pii: 10.1038/s41388-022-02409.
    PubMed     Abstract available

  4. QUEK LE, van Geldermalsen M, Guan YF, Wahi K, et al
    Glutamine addiction promotes glucose oxidation in triple-negative breast cancer.
    Oncogene. 2022 Jul 18. pii: 10.1038/s41388-022-02408.
    PubMed     Abstract available

    June 2022
  5. SHEN J, Huang Q, Jia W, Feng S, et al
    YAP1 induces invadopodia formation by transcriptionally activating TIAM1 through enhancer in breast cancer.
    Oncogene. 2022 Jun 30. pii: 10.1038/s41388-022-02344.
    PubMed     Abstract available

  6. BUSCHHAUS JM, Rajendran S, Humphries BA, Cutter AC, et al
    Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer.
    Oncogene. 2022 Jun 22. pii: 10.1038/s41388-022-02385.
    PubMed     Abstract available

  7. RONG Z, Zhang L, Li Z, Xiao Z, et al
    Correction: SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling.
    Oncogene. 2022 Jun 14. pii: 10.1038/s41388-022-02374.

  8. KUMARASAMY V, Nambiar R, Wang J, Rosenheck H, et al
    RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.
    Oncogene. 2022 Jun 9. pii: 10.1038/s41388-022-02362.
    PubMed     Abstract available

  9. MEIJER TG, Nguyen L, Van Hoeck A, Sieuwerts AM, et al
    Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Oncogene. 2022;41:3498-3506.
    PubMed     Abstract available

    May 2022
  10. RATZE MAK, Koorman T, Sijnesael T, Bassey-Archibong B, et al
    Correction: Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
    Oncogene. 2022 May 24. pii: 10.1038/s41388-022-02355.

  11. ZHAO Y, Sun H, Zhao Y, Liu Q, et al
    NSrp70 suppresses metastasis in triple-negative breast cancer by modulating Numb/TbetaR1/EMT axis.
    Oncogene. 2022 May 14. pii: 10.1038/s41388-022-02349.
    PubMed     Abstract available

  12. SIMOND AM, Bui T, Zuo D, Sanguin-Gendreau V, et al
    Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer.
    Oncogene. 2022 May 10. pii: 10.1038/s41388-022-02323.
    PubMed     Abstract available

  13. KIM JY, Cho TM, Park JM, Park S, et al
    A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.
    Oncogene. 2022 May 2. pii: 10.1038/s41388-022-02269.
    PubMed     Abstract available

  14. LIM JS, Lee KW, Ko KP, Jeong SI, et al
    XAF1 destabilizes estrogen receptor alpha through the assembly of a BRCA1-mediated destruction complex and promotes estrogen-induced apoptosis.
    Oncogene. 2022;41:2897-2908.
    PubMed     Abstract available

  15. CHADET S, Allard J, Brisson L, Lopez-Charcas O, et al
    P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition.
    Oncogene. 2022;41:2920-2931.
    PubMed     Abstract available

  16. PANG Z, Dong X, Deng H, Wang C, et al
    MUC1 triggers lineage plasticity of Her2 positive mammary tumors.
    Oncogene. 2022;41:3064-3078.
    PubMed     Abstract available

    April 2022
  17. KIM Y, Ko JY, Lee SB, Oh S, et al
    Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer.
    Oncogene. 2022 Apr 30. pii: 10.1038/s41388-022-02326.
    PubMed     Abstract available

  18. RATZE MAK, Koorman T, Sijnesael T, Bassey-Archibong B, et al
    Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
    Oncogene. 2022 Apr 18. pii: 10.1038/s41388-022-02314.
    PubMed     Abstract available

  19. WU S, Guo B, Zhang L, Zhu X, et al
    A micropeptide XBP1SBM encoded by lncRNA promotes angiogenesis and metastasis of TNBC via XBP1s pathway.
    Oncogene. 2022;41:2163-2172.
    PubMed     Abstract available

    March 2022
  20. BERTOLINI I, Perego M, Ghosh JC, Kossenkov AV, et al
    NFkappaB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment.
    Oncogene. 2022 Mar 30. pii: 10.1038/s41388-022-02280.
    PubMed     Abstract available

  21. YANG YS, Jia XZ, Lu QY, Cai SL, et al
    Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells.
    Oncogene. 2022 Mar 29. pii: 10.1038/s41388-022-02278.
    PubMed     Abstract available

  22. KOORMAN T, Jansen KA, Khalil A, Haughton PD, et al
    Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment.
    Oncogene. 2022 Mar 15. pii: 10.1038/s41388-022-02258.
    PubMed     Abstract available

  23. RONG Z, Zhang L, Li Z, Xiao Z, et al
    SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling.
    Oncogene. 2022 Mar 11. pii: 10.1038/s41388-022-02259.
    PubMed     Abstract available

  24. LIU R, Yang G, Bao M, Zhou Z, et al
    STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression.
    Oncogene. 2022 Mar 2. pii: 10.1038/s41388-022-02252.
    PubMed     Abstract available

    February 2022
  25. TURDO A, Gaggianesi M, Di Franco S, Veschi V, et al
    Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51.
    Oncogene. 2022 Feb 25. pii: 10.1038/s41388-022-02239.
    PubMed     Abstract available

  26. LIU Y, Ma L, Hua F, Min Z, et al
    Correction: Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer.
    Oncogene. 2022 Feb 22. pii: 10.1038/s41388-022-02217.

  27. ZHANG Y, Dho SE, Othman K, Simpson CD, et al
    Numb exon 9 inclusion regulates Integrinbeta5 surface expression and promotes breast cancer metastasis.
    Oncogene. 2022 Feb 18. pii: 10.1038/s41388-022-02225.
    PubMed     Abstract available

  28. SUN T, Wu Z, Wang X, Wang Y, et al
    Correction to: LNC942 promoting METTL14-mediated m 6 A methylation in breast cancer cell proliferation and progression.
    Oncogene. 2022 Feb 15. pii: 10.1038/s41388-022-02194.

  29. GUO XY, Liu TT, Zhu WJ, Liu HT, et al
    CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis.
    Oncogene. 2022 Feb 11. pii: 10.1038/s41388-022-02232.
    PubMed     Abstract available

  30. XU LM, Zhang J, Ma Y, Yuan YJ, et al
    MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG.
    Oncogene. 2022 Feb 4. pii: 10.1038/s41388-022-02211.
    PubMed     Abstract available

  31. MA A, Tang M, Zhang L, Wang B, et al
    Correction to: USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis.
    Oncogene. 2022 Feb 3. pii: 10.1038/s41388-022-02215.

  32. BIONDINI M, Kiepas A, El-Houjeiri L, Annis MG, et al
    HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
    Oncogene. 2022 Feb 2. pii: 10.1038/s41388-022-02206.
    PubMed     Abstract available

    January 2022
  33. HOWLEY BV, Mohanty B, Dalton A, Grelet S, et al
    The ubiquitin E3 ligase ARIH1 regulates hnRNP E1 protein stability, EMT and breast cancer progression.
    Oncogene. 2022 Jan 31. pii: 10.1038/s41388-022-02199.
    PubMed     Abstract available

  34. ZOU H, Luo J, Guo Y, Liu Y, et al
    RNA-binding protein complex LIN28/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7.
    Oncogene. 2022 Jan 31. pii: 10.1038/s41388-022-02198.
    PubMed     Abstract available

  35. MA Y, Zhang H, Chen C, Liu L, et al
    TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer.
    Oncogene. 2022 Jan 28. pii: 10.1038/s41388-022-02204.
    PubMed     Abstract available

  36. ZIGROSSI A, Hong LK, Ekyalongo RC, Cruz-Alvarez C, et al
    SELENOF is a new tumor suppressor in breast cancer.
    Oncogene. 2022 Jan 27. pii: 10.1038/s41388-021-02158.
    PubMed     Abstract available

  37. OKPECHI SC, Yousefi H, Nguyen K, Cheng T, et al
    Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.
    Oncogene. 2022 Jan 22. pii: 10.1038/s41388-021-02150.
    PubMed     Abstract available

  38. AVALLE L, Raggi L, Monteleone E, Savino A, et al
    STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts.
    Oncogene. 2022 Jan 18. pii: 10.1038/s41388-021-02172.
    PubMed     Abstract available

  39. LIU Y, Ma L, Hua F, Min Z, et al
    Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer.
    Oncogene. 2022 Jan 13. pii: 10.1038/s41388-021-02061.
    PubMed     Abstract available

  40. SHU L, Chen A, Li L, Yao L, et al
    NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation.
    Oncogene. 2022 Jan 7. pii: 10.1038/s41388-021-02142.
    PubMed     Abstract available

  41. BUI T, Gu Y, Ancot F, Sanguin-Gendreau V, et al
    Emergence of beta1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment.
    Oncogene. 2022;41:527-537.
    PubMed     Abstract available

  42. CICEK E, Circir A, Oyken M, Akbulut Caliskan O, et al
    EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers.
    Oncogene. 2022;41:220-232.
    PubMed     Abstract available

  43. KUIKEN HJ, Dhakal S, Selfors LM, Friend CM, et al
    Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts.
    Oncogene. 2022;41:112-124.
    PubMed     Abstract available

    December 2021
  44. ZHANG S, Guo X, Liu X, Zhong Z, et al
    Correction to: Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation.
    Oncogene. 2021 Dec 20. pii: 10.1038/s41388-021-02129.

  45. CAO X, Geradts J, Dewhirst MW, Lo HW, et al
    Correction: Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.
    Oncogene. 2021 Dec 9. pii: 10.1038/s41388-021-02043.

    November 2021
  46. KONG Y, Zhang Y, Wang H, Kan W, et al
    Inner nuclear membrane protein TMEM201 promotes breast cancer metastasis by positive regulating TGFbeta signaling.
    Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02098.
    PubMed     Abstract available

  47. LI Y, Liu HT, Chen X, Wang YW, et al
    Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer.
    Oncogene. 2021 Nov 9. pii: 10.1038/s41388-021-02083.
    PubMed     Abstract available

  48. RUIZ-TORRES SJ, Bourn JR, Benight NM, Hunt BG, et al
    Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35.
    Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02091.
    PubMed     Abstract available

  49. YI B, Wang S, Wang X, Liu Z, et al
    CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer.
    Oncogene. 2021 Nov 2. pii: 10.1038/s41388-021-02089.
    PubMed     Abstract available

  50. ROUKENS MG, Frederiks CL, Seinstra D, Braccioli L, et al
    Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation.
    Oncogene. 2021;40:6343-6353.
    PubMed     Abstract available

  51. BOLADO-CARRANCIO A, Lee M, Ewing A, Muir M, et al
    ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling.
    Oncogene. 2021;40:6235-6247.
    PubMed     Abstract available

    October 2021
  52. TANG SC, Lion Q, Peulen O, Chariot P, et al
    The E3 ligase COP1 promotes ERalpha signaling and suppresses EMT in breast cancer.
    Oncogene. 2021 Oct 29. pii: 10.1038/s41388-021-02038.
    PubMed     Abstract available

  53. CHERADAME L, Guerrera IC, Gaston J, Schmitt A, et al
    STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway.
    Oncogene. 2021 Oct 8. pii: 10.1038/s41388-021-02037.
    PubMed     Abstract available

  54. BLOCK CJ, Mitchell AV, Wu L, Glassbrook J, et al
    RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
    Oncogene. 2021 Oct 4. pii: 10.1038/s41388-021-02030.
    PubMed     Abstract available

    September 2021
  55. LIU Z, Sang X, Wang M, Liu Y, et al
    Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2.
    Oncogene. 2021 Sep 23. pii: 10.1038/s41388-021-02015.
    PubMed     Abstract available

  56. VAFAIZADEH V, Buechel D, Rubinstein N, Kalathur RKR, et al
    The interactions of Bcl9/Bcl9L with beta-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
    Oncogene. 2021 Sep 20. pii: 10.1038/s41388-021-02016.
    PubMed     Abstract available

  57. PALMA FR, Ratti BA, Paviani V, Coelho DR, et al
    AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism.
    Oncogene. 2021;40:5455-5467.
    PubMed     Abstract available

    August 2021
  58. SUN J, Gaidosh G, Xu Y, Mookhtiar A, et al
    RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells.
    Oncogene. 2021 Aug 9. pii: 10.1038/s41388-021-01985.
    PubMed     Abstract available

  59. ZHANG F, Li P, Liu S, Yang M, et al
    beta-Catenin-CCL2 feedback loop mediates crosstalk between cancer cells and macrophages that regulates breast cancer stem cells.
    Oncogene. 2021 Aug 3. pii: 10.1038/s41388-021-01986.
    PubMed     Abstract available

  60. YAN Y, Narayan A, Cho S, Cheng Z, et al
    CRYbetaB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer.
    Oncogene. 2021 Aug 2. pii: 10.1038/s41388-021-01975.
    PubMed     Abstract available

  61. MAJHI PD, Griner NB, Mayfield JA, Compton S, et al
    Genetic modifiers regulating DNA replication and double-strand break repair are associated with differences in mammary tumors in mouse models of Li-Fraumeni syndrome.
    Oncogene. 2021;40:5026-5037.
    PubMed     Abstract available

    July 2021
  62. ZHANG S, Guo X, Liu X, Zhong Z, et al
    Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation.
    Oncogene. 2021 Jul 30. pii: 10.1038/s41388-021-01970.
    PubMed     Abstract available

  63. WHATELY KM, Voronkova MA, Maskey A, Gandhi J, et al
    Nuclear Aurora-A kinase-induced hypoxia signaling drives early dissemination and metastasis in breast cancer: implications for detection of metastatic tumors.
    Oncogene. 2021 Jul 29. pii: 10.1038/s41388-021-01969.
    PubMed     Abstract available

  64. SETO-TETSUO F, Arioka M, Miura K, Inoue T, et al
    DIF-1 inhibits growth and metastasis of triple-negative breast cancer through AMPK-mediated inhibition of the mTORC1-S6K signaling pathway.
    Oncogene. 2021 Jul 24. pii: 10.1038/s41388-021-01958.
    PubMed     Abstract available

  65. ZHANG Y, Shi G, Zhang H, Xiong Q, et al
    Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway.
    Oncogene. 2021 Jul 16. pii: 10.1038/s41388-021-01944.
    PubMed     Abstract available

  66. CLEMENTS ME, Holtslander L, Edwards C, Todd V, et al
    HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.
    Oncogene. 2021 Jul 10. pii: 10.1038/s41388-021-01931.
    PubMed     Abstract available

  67. YU P, Zhu X, Zhu JL, Han YB, et al
    The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer.
    Oncogene. 2021 Jul 9. pii: 10.1038/s41388-021-01933.
    PubMed     Abstract available

  68. HAMALIAN S, Guth R, Runa F, Sanchez F, et al
    A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.
    Oncogene. 2021 Jul 8. pii: 10.1038/s41388-021-01906.
    PubMed     Abstract available

  69. ZHANG J, Liu Y, Tan J, Zhang Y, et al
    Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC.
    Oncogene. 2021;40:4783-4795.
    PubMed     Abstract available

  70. ZHAO Z, Guo Y, Liu Y, Sun L, et al
    Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer.
    Oncogene. 2021;40:4604-4614.
    PubMed     Abstract available

  71. LIU X, Li L, Si F, Huang L, et al
    NK and NKT cells have distinct properties and functions in cancer.
    Oncogene. 2021;40:4521-4537.
    PubMed     Abstract available

    June 2021
  72. QIU Y, Yang Y, Yang R, Liu C, et al
    Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
    Oncogene. 2021 Jun 25. pii: 10.1038/s41388-021-01896.
    PubMed     Abstract available

  73. BI X, Lou P, Song Y, Sheng X, et al
    Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway.
    Oncogene. 2021 Jun 21. pii: 10.1038/s41388-021-01873.
    PubMed     Abstract available

  74. SHARIATI M, Evans KW, Zheng X, Bristow CA, et al
    Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
    Oncogene. 2021 Jun 9. pii: 10.1038/s41388-021-01819.
    PubMed     Abstract available

  75. TRUONG TH, Benner EA, Hagen KM, Temiz NA, et al
    PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER(+) breast cancer.
    Oncogene. 2021 Jun 8. pii: 10.1038/s41388-021-01871.
    PubMed     Abstract available

  76. QIAO Y, Jin T, Guan S, Cheng S, et al
    Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01845.
    PubMed     Abstract available

  77. PROKAKIS E, Dyas A, Grun R, Fritzsche S, et al
    USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response.
    Oncogene. 2021;40:4004-4018.
    PubMed     Abstract available

    May 2021
  78. LODILLINSKY C, Fuhrmann L, Irondelle M, Pylypenko O, et al
    Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance.
    Oncogene. 2021 May 19. pii: 10.1038/s41388-021-01826.
    PubMed     Abstract available

  79. XU Q, Zhang J, Telfer BA, Zhang H, et al
    The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.
    Oncogene. 2021 May 12. pii: 10.1038/s41388-021-01798.
    PubMed     Abstract available

  80. LAGER TW, Conner C, Keating CR, Warshaw JN, et al
    Cell surface GRP78 and Dermcidin cooperate to regulate breast cancer cell migration through Wnt signaling.
    Oncogene. 2021 May 12. pii: 10.1038/s41388-021-01821.
    PubMed     Abstract available

  81. WILLIAMS CB, Phelps-Polirer K, Dingle IP, Williams CJ, et al
    Correction: HUNK phosphorylates EGFR to regulate breast cancer metastasis.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01797.

  82. STEBBING J, Zhang H, Xu Y, Lit LC, et al
    Correction: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
    Oncogene. 2021 May 4. pii: 10.1038/s41388-021-01794.

    April 2021
  83. LIU L, Zhang X, Ding H, Liu X, et al
    Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS.
    Oncogene. 2021 Apr 29. pii: 10.1038/s41388-021-01785.
    PubMed     Abstract available

  84. STEBBING J, Zhang H, Xu Y, Lit LC, et al
    Correction to: KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.
    Oncogene. 2021 Apr 22. pii: 10.1038/s41388-021-01759.

  85. TRAPHAGEN NA, Hosford SR, Jiang A, Marotti JD, et al
    High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
    Oncogene. 2021 Apr 19. pii: 10.1038/s41388-021-01782.
    PubMed     Abstract available

  86. KIM ES, Nam SM, Song HK, Lee S, et al
    CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity.
    Oncogene. 2021 Apr 8. pii: 10.1038/s41388-021-01758.
    PubMed     Abstract available

  87. MAI J, Peng XD, Tang J, Du T, et al
    AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation.
    Oncogene. 2021;40:2422-2436.
    PubMed     Abstract available

    March 2021
  88. LIANG Y, Song X, Li Y, Su P, et al
    Correction: circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.
    Oncogene. 2021 Mar 25. pii: 10.1038/s41388-021-01750.

  89. WANG X, Feng M, Xiao T, Guo B, et al
    BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
    Oncogene. 2021 Mar 25. pii: 10.1038/s41388-021-01756.
    PubMed     Abstract available

  90. HUTCHINSON SA, Websdale A, Cioccoloni G, Roberg-Larsen H, et al
    Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer.
    Oncogene. 2021 Mar 19. pii: 10.1038/s41388-021-01720.
    PubMed     Abstract available

  91. WANG YH, Chan YT, Hung TH, Hung JT, et al
    Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation.
    Oncogene. 2021 Mar 19. pii: 10.1038/s41388-021-01729.
    PubMed     Abstract available

  92. MARTINEZ-ORDONEZ A, Seoane S, Avila L, Eiro N, et al
    POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation.
    Oncogene. 2021 Mar 13. pii: 10.1038/s41388-021-01740.
    PubMed     Abstract available

  93. CHEN T, Wang X, Li C, Zhang H, et al
    CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation.
    Oncogene. 2021 Mar 13. pii: 10.1038/s41388-021-01739.
    PubMed     Abstract available

  94. KIM H, Son S, Ko Y, Shin I, et al
    CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer.
    Oncogene. 2021 Mar 10. pii: 10.1038/s41388-021-01731.
    PubMed     Abstract available

  95. BERDIEL-ACER M, Maia A, Hristova Z, Borgoni S, et al
    Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts.
    Oncogene. 2021 Mar 10. pii: 10.1038/s41388-021-01719.
    PubMed     Abstract available

  96. JALALIRAD M, Haddad TC, Salisbury JL, Radisky D, et al
    Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01711.
    PubMed     Abstract available

  97. REINSBOROUGH CW, Ipas H, Abell NS, Gouws EB, et al
    BCDIN3D RNA methyltransferase stimulates Aldolase C expression and glycolysis through let-7 microRNA in breast cancer cells.
    Oncogene. 2021 Mar 4. pii: 10.1038/s41388-021-01702.
    PubMed     Abstract available

  98. SIRKISOON SR, Carpenter RL, Rimkus T, Doheny D, et al
    Correction: TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment.
    Oncogene. 2021 Mar 2. pii: 10.1038/s41388-020-01620.

  99. GE LP, Jin X, Yang YS, Liu XY, et al
    Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
    Oncogene. 2021 Mar 2. pii: 10.1038/s41388-021-01655.
    PubMed     Abstract available

  100. VARONE E, Decio A, Chernorudskiy A, Minoli L, et al
    The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions.
    Oncogene. 2021;40:1721-1736.
    PubMed     Abstract available

  101. AHMED SF, Buetow L, Gabrielsen M, Lilla S, et al
    E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Oncogene. 2021;40:2149-2164.
    PubMed     Abstract available

  102. LIN CC, Yang WH, Lin YT, Tang X, et al
    DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
    Oncogene. 2021;40:2018-2034.
    PubMed     Abstract available

  103. YE Z, Wang D, Lu Y, He Y, et al
    Vacuolin-1 inhibits endosomal trafficking and metastasis via CapZbeta.
    Oncogene. 2021;40:1775-1791.
    PubMed     Abstract available

    February 2021
  104. WU R, Li K, Yuan M, Luo KQ, et al
    Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells.
    Oncogene. 2021 Feb 24. pii: 10.1038/s41388-021-01691.
    PubMed     Abstract available

  105. BUTTI R, Nimma R, Kundu G, Bulbule A, et al
    Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression.
    Oncogene. 2021 Feb 18. pii: 10.1038/s41388-021-01663.
    PubMed     Abstract available

  106. WANG G, Wang J, Chang A, Cheng D, et al
    Correction to: Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2.
    Oncogene. 2021 Feb 10. pii: 10.1038/s41388-021-01652.

  107. KUNG CP, Cottrell KA, Ryu S, Bramel ER, et al
    Correction to: Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01669.

  108. PAN JK, Lin CH, Kuo YL, Ger LP, et al
    MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer.
    Oncogene. 2021 Feb 3. pii: 10.1038/s41388-021-01654.
    PubMed     Abstract available

  109. CHEN D, Parker TM, Bhat-Nakshatri P, Chu X, et al
    Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.
    Oncogene. 2021;40:1332-1346.
    PubMed     Abstract available

  110. AL-AKHRASS H, Conway JRW, Poulsen ASA, Paatero I, et al
    A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance.
    Oncogene. 2021;40:1300-1317.
    PubMed     Abstract available

  111. GU G, Tian L, Herzog SK, Rechoum Y, et al
    Hormonal modulation of ESR1 mutant metastasis.
    Oncogene. 2021;40:997-1011.
    PubMed     Abstract available

    January 2021
  112. ABRIL YLN, Fernandez IR, Hong JY, Chiang YL, et al
    Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer.
    Oncogene. 2021 Jan 21. pii: 10.1038/s41388-020-01637.
    PubMed     Abstract available

  113. ZHU P, He F, Hou Y, Tu G, et al
    A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability.
    Oncogene. 2021 Jan 19. pii: 10.1038/s41388-020-01638.
    PubMed     Abstract available

  114. ZHANG H, Wong CCL, Wei H, Gilkes DM, et al
    Correction: HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs.
    Oncogene. 2021 Jan 15. pii: 10.1038/s41388-020-01618.

  115. VARESLIJA D, Ward E, Purcell SP, Cosgrove NS, et al
    Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01606.
    PubMed     Abstract available

  116. PANTANO F, Croset M, Driouch K, Bednarz-Knoll N, et al
    Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01603.
    PubMed     Abstract available

  117. YOUSEFI H, Vatanmakanian M, Mahdiannasser M, Mashouri L, et al
    Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance.
    Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01588.
    PubMed     Abstract available

  118. TIEDE S, Kalathur RKR, Luond F, von Allmen L, et al
    Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression.
    Oncogene. 2021;40:12-27.
    PubMed     Abstract available

    December 2020
  119. KONG D, Zhou H, Neelakantan D, Hughes CJ, et al
    VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk.
    Oncogene. 2020 Dec 9. pii: 10.1038/s41388-020-01539.
    PubMed     Abstract available

  120. HAN J, Qu H, Han M, Ding Y, et al
    MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer.
    Oncogene. 2020 Dec 3. pii: 10.1038/s41388-020-01574.
    PubMed     Abstract available

  121. SONG Y, Zeng S, Zheng G, Chen D, et al
    FOXO3a-driven miRNA signatures suppresses VEGF-A/NRP1 signaling and breast cancer metastasis.
    Oncogene. 2020 Dec 1. pii: 10.1038/s41388-020-01562.
    PubMed     Abstract available

    November 2020
  122. ATTALLA S, Taifour T, Bui T, Muller W, et al
    Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo.
    Oncogene. 2020 Nov 24. pii: 10.1038/s41388-020-01560.
    PubMed     Abstract available

  123. GUAN X, Deng H, Choi UL, Li Z, et al
    EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis.
    Oncogene. 2020;39:7127-7141.
    PubMed     Abstract available

    October 2020
  124. ABDULLAH A, Akhand SS, Paez JSP, Brown W, et al
    Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer.
    Oncogene. 2020 Oct 30. pii: 10.1038/s41388-020-01530.
    PubMed     Abstract available

  125. KUNG CP, Cottrell KA, Ryu S, Bramel ER, et al
    Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer.
    Oncogene. 2020 Oct 27. pii: 10.1038/s41388-020-01515.
    PubMed     Abstract available

  126. ZHENG X, Lu S, He Z, Huang H, et al
    MCU-dependent negative sorting of miR-4488 to extracellular vesicles enhances angiogenesis and promotes breast cancer metastatic colonization.
    Oncogene. 2020 Oct 16. pii: 10.1038/s41388-020-01514.
    PubMed     Abstract available

  127. LI Y, Li L, Qin J, Wu J, et al
    OSR1 phosphorylates the Smad2/3 linker region and induces TGF-beta1 autocrine to promote EMT and metastasis in breast cancer.
    Oncogene. 2020 Oct 13. pii: 10.1038/s41388-020-01499.
    PubMed     Abstract available

  128. ZHANG L, Qin Y, Wu G, Wang J, et al
    PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1.
    Oncogene. 2020 Oct 9. pii: 10.1038/s41388-020-01494.
    PubMed     Abstract available

  129. CHEN H, Libring S, Ruddraraju KV, Miao J, et al
    SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer.
    Oncogene. 2020 Oct 8. pii: 10.1038/s41388-020-01488.
    PubMed     Abstract available

  130. WANG S, Somisetty VS, Bai B, Chernukhin I, et al
    The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.
    Oncogene. 2020;39:6300-6312.
    PubMed     Abstract available

    September 2020
  131. WANG G, Wang J, Chang A, Cheng D, et al
    Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01481.
    PubMed     Abstract available

  132. ZHU J, Li X, Su P, Xue M, et al
    The ubiquitin ligase RNF181 stabilizes ERalpha and modulates breast cancer progression.
    Oncogene. 2020 Sep 24. pii: 10.1038/s41388-020-01464.
    PubMed     Abstract available

  133. LI LY, Chen XS, Wang KS, Guan YD, et al
    RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKalpha2-mediated autophagy.
    Oncogene. 2020 Sep 21. pii: 10.1038/s41388-020-01447.
    PubMed     Abstract available

    August 2020
  134. WANG M, Long K, Li E, Li L, et al
    DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation.
    Oncogene. 2020;39:5507-5519.
    PubMed     Abstract available

    July 2020
  135. CHAI TF, Manu KA, Casey PJ, Wang M, et al
    Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal.
    Oncogene. 2020;39:5373-5389.
    PubMed     Abstract available

    June 2020
  136. AL-ZAHRANI KN, Abou-Hamad J, Cook DP, Pryce BR, et al
    Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers.
    Oncogene. 2020;39:4592-4602.
    PubMed     Abstract available

  137. TABATABAEIAN H, Rao A, Ramos A, Chu T, et al
    The emerging roles of WBP2 oncogene in human cancers.
    Oncogene. 2020;39:4621-4635.
    PubMed     Abstract available

  138. PANCHOLI S, Ribas R, Simigdala N, Schuster E, et al
    Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Oncogene. 2020;39:4781-4797.
    PubMed     Abstract available

    April 2020
  139. KLUZ PN, Kolb R, Xie Q, Borcherding N, et al
    Cancer cell-intrinsic function of CD177 in attenuating beta-catenin signaling.
    Oncogene. 2020;39:2877-2889.
    PubMed     Abstract available

  140. JEANNOT E, Darrigues L, Michel M, Stern MH, et al
    A single droplet digital PCR for ESR1 activating mutations detection in plasma.
    Oncogene. 2020;39:2987-2995.
    PubMed     Abstract available

  141. FRANCART ME, Vanwynsberghe AM, Lambert J, Bourcy M, et al
    Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis.
    Oncogene. 2020;39:3680-3692.
    PubMed     Abstract available

    March 2020
  142. HSU BE, Roy J, Mouhanna J, Rayes RF, et al
    C3a elicits unique migratory responses in immature low-density neutrophils.
    Oncogene. 2020;39:2612-2623.
    PubMed     Abstract available

  143. BRUMMER G, Fang W, Smart C, Zinda B, et al
    CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments.
    Oncogene. 2020;39:2275-2289.
    PubMed     Abstract available

    February 2020
  144. LEFORT S, Tan S, Balani S, Rafn B, et al
    Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation.
    Oncogene. 2020;39:1957-1968.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.